Combination of trastuzumab and taxanes from preclinical data to clinical application;Place de l'association trastuzumab et taxanes dans la prise en charge thérapeutique du cancer du sein: De la préclinique à la clinique

Bulletin du Cancer

Volumn 90, Issue 7, 2003, Pages 614-622

  Campone, Mario ^a   Merlin, Jean Louis ^b   Fumoleau, Pierre ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Breast metastatic cancer; Resistance; Taxane; Trastuzumab

Indexed keywords

MEMBRANE PROTEIN; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST METASTASIS; CARCINOGENESIS; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; PROTEIN BINDING; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 0041924868     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Piccart M, Dochy E, Cardoso F. News in the medical treatment of breast cancer. Bull Cancer 2003 ; 90 : 46-52.
2. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986 ; 319 : 226-30.
3. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985 ; 230 : 1132-9.
4. Jarvinen TAH, Liu ET. Effects of HER-2/neu on chemosensitivity of tumor cells. Drug Resist Update 2000 ; 3 : 310-324.
5. Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioassays 1998 ; 20 : 41-8.
6. Tzahar E, Yarden Y. The ErbB-2/HER-2 oncogenic receptor of adenocarcinomas : from orphanhood to multiple stromal ligands. Biochem Biophys Acta 1998 ; 1377 : M25-37.
7. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network : receptor heterodimerization in development and cancer. EMBO J 2000 ; 19 : 3159-67.
8. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000 ; 77 : 25-79.
9. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER-2/neu expression in lung tumors. Semin Oncol 2002 ; 29 (suppl. 4) : 51-8.
10. Busse D, Doughty RS, Arteaga CL. HER-2/neu (ErbB-2) and the cell cycle. Semin Oncol 2000 ; 27 (suppl. 11) : 3-8.
11. Clurman BE, Porter P. New insights into the tumor suppression function of p27Kip1. Proc Natl Acad Sci USA 1998 ; 95 : 15158-60.
12. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000 ; 60 : 6841-5.
13. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000 ; 275 : 8027-31.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL Human breast cancer : correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987 ; 235 : 177-82.
15. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Mullet WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992 ; 89 : 1O578-82.
16. Tan M, Yao J, Yu D. Overexpression of c-ErbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997 : 1199-205.
17. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized antip185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996 ; 14 : 737-44.
18. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993 ; 37 : 255-63.
19. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer : taking the HER2 protooncogene to the clinic. J Clin Immunol 1991 ; 11 : 117-27.
20. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000 ; 60 : 3384-8.
21. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998 ; 2 : 581-91.
22. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998 ; 16 : 2087-94.
23. Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER-2 expressing human breast cancer cell lines. Ann Oncol 2002 ; 13 : 1748-8.
24. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996 ; 13 : 1359-65.
25. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998 ; 58 : 2825-31.
26. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997 ; 15 : 537-47.
27. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000 ; 156 : 839-47.
28. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998 ; 17 : 2235-49.
29. Alaoui-Jamali MA, Paterson J, Al Moustafa AE, Yen L. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance : mechanisms and implications. Biochem Cell Biol 1997 ; 75 : 315-25.
30. Tsai CM, Chang KT, Li L, Perng RP, Yang LY. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 2000 ; 91 : 213-22.
31. Pegram M, Hsu S, Lewis G, Piettas R, Betyt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human cancers. Oncogene 1999 ; 18 : 2241-51.
32. Konecny G, Pegram M, Betyt M, Untch M, Slamon DJ. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with Her2/neu overexpression. Proc San Antonio Breast Cancer Meeting 1999 ; abstract 467.
33. Buttis HA. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab. Sem Oncol 2000 ; 27 (suppl. 3) : 19-23.
34. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000 ; 141 : 4503-11.
35. Kumat R, Mandal M, Vadlamudi R. New insights into anti-HER2 receptor monoclonal antibody research. Semin Oncol 2000 ; 27 : 84-91.
36. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783-92.
37. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001 ; 19 : 2587-95.
38. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002 ; 35.
39. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer : a pilot study. J Clin Oncol 2003 ; 21 : 46-5.
40. Butris III HA. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001 ; 28 (suppl. 3) : 38-44.
41. Nicholson BP, Thor AD, Goldstein LJ, Merkel DE, Gradishar WJ, Sledge GW. Weekly docetaxel (D) and rhumabher2 (H) combination therapy as first-or second-line treatment for metastatic breast cancer. Proc Am Soc Clin Oncol 2000 ; 18 : 549.
42. Esteva FJ, Valero V, Booser D, Guetta LT, Muttay JL, Pusztai L, et al. Phase II study weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 ; 20 : 1800-8.
43. Nabholtz JM, Pienkowski T, Nothfelt D, Eierman W, Quan E, Fumoleau P, et al. Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors overexpressing the HER2-neu proto-oncogene Eur J Cancer 2001 ; 37 (suppl. 6) : 695.